Tysabri Demonstrates Significant Health-Related Quality-of-Life Improvements for Multiple Sclerosis Patients in Study Published in Annals of Neurology
CAMBRIDGE, Mass.& DUBLIN, Ireland--(BUSINESS WIRE)--Aug 20, 2007 - Biogen Idec and Elan Corporation, plc announced today the publication of results demonstrating that patients treated with Tysabri (natalizumab) showed a significant improvement in health-related quality-of-life (HRQoL) measures when compared to placebo. These results are from the first Phase III multiple sclerosis (MS) studies that have demonstrated improvement on HRQoL measures in patients with relapsing forms of MS.
CAMBRIDGE, Mass.& DUBLIN, Ireland--(BUSINESS WIRE)--Aug 20, 2007 - Biogen Idec and Elan Corporation, plc announced today the publication of results demonstrating that patients treated with Tysabri (natalizumab) showed a significant improvement in health-related quality-of-life (HRQoL) measures when compared to placebo. These results are from the first Phase III multiple sclerosis (MS) studies that have demonstrated improvement on HRQoL measures in patients with relapsing forms of MS.
posted by Bill at 11:14 AM
0 Comments:
Post a Comment
<< Home